

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**EVERGRANDE HEALTH
INDUSTRY GROUP**

EVERGRANDE HEALTH INDUSTRY GROUP LIMITED

恒大健康產業集團有限公司

(a company incorporated in Hong Kong with limited liability)

(Stock code: 708)

**RESIGNATION OF EXECUTIVE DIRECTOR
AND**

APPOINTMENT OF EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER

RESIGNATION AND APPOINTMENT OF DIRECTORS

The Board hereby announces the following change of Directors with effect from 23 March 2016:

1. Mr. Tong Ming has resigned as an executive Director; and
2. Mr. Peng Sheng has been appointed as an executive Director and the Chief Executive Officer of the Company.

RESIGNATION OF DIRECTOR

The board of directors (the “**Board**” and each “**Director**”) of Evergrande Health Industry Group Limited (the “**Company**”) announces that Mr. Tong Ming (“**Mr. Tong**”) has resigned as an executive Director with effect from 23 March 2016 due to his other career development.

Mr. Tong confirmed that he had no disagreement with the Board and there was no matter relating to his resignation that needs to be brought to the attention of the holders of the securities of the Company.

The Board would like to express its gratitude to Mr. Tong for his valuable contribution to the Company during his term of office.

APPOINTMENT OF EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER

The Board is pleased to announce that Mr. Peng Sheng (“**Mr. Peng**”) has been appointed as an executive Director and the Chief Executive Officer of the Company with effect from 23 March 2016.

Mr. Peng, aged 40, graduated from University of Science and Technology of China and obtained a master’s degree from the Department of Modern Physics in 1999 and a bachelor’s degree from the Department of Physics in 1996. He has broad international perspective and extensive management and working experience in multinational companies. He has managed businesses and teams in the United States of America (the “US”), Europe and China. Before joining the Company, Mr. Peng, as an expert returning from abroad, was the Managing Vice President and the Chief Technology Officer of Guangdong Hengjian Nucleus Medical Industry Co., Ltd. under the Guangdong State-owned Assets Supervision and Administration Commission of the State Council to lead a series of significant commercial negotiations on technology and the development of particle radiation therapy equipment. Before returning to China, Mr. Peng worked in Varian Medical Systems, Inc. of the US, a world leader in radiation therapy equipment for several years to lead the teams in the US and Europe to develop the proton therapy device of the new generation. Before that, Mr. Peng had worked for many national laboratories in the US and the SLAC National Accelerator Laboratory for several years and was a famous expert in large-scale computer control system and information processing.

Mr. Peng has entered into a service contract with the Company for a term of three years as a Director and the Chief Executive Officer of the Company, and is subject to retirement by rotation at least once every three years and re-election at the general meetings of the Company in accordance with the articles of association of the Company. Pursuant to the service contract, Mr. Peng will receive a director’s fee of RMB15,000 per month (with discretionary bonus) as an executive Director and the Chief Executive Officer of the Company, which is recommended with reference to his duties and responsibilities as an executive Director and the Chief Executive Officer of the Company, the Company’s remuneration policy and the prevailing market conditions.

To the knowledge of the Company, Mr. Peng Sheng, as of the date of this announcement,

- (a) has not held any other directorships in any other listed public companies in the last three years and does not have any relationship with any Director, senior management or substantial or controlling shareholder of the Company;
- (b) does not have any interests in the shares of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong);
- (c) does not hold any other position in the Company or any of its subsidiaries; and
- (d) has no other information that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules, nor is there any matter that needs to be brought to the attention of the holders of the securities of the Company in relation to his appointment as a Director.

The Board hereby welcomes Mr. Peng to serve as a member of the Board and the Chief Executive Officer of the Company.

By Order of the Board
Evergrande Health Industry Group Limited
Tan Chaohui
Chairperson

Hong Kong, 23 March 2016

As at the date of this announcement, the executive directors of the Company are Ms. Tan Chaohui, Mr. Han Xiaoran and Mr. Peng Sheng; and the independent non-executive directors of the Company are Mr. Chau Shing Yim, David, Mr. Guo Jianwen and Mr. Xie Wu.